

Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Horizon Europe

Generato il: 8 ottobre 2026

● APERTO

Codice

HORIZON-MISS-2027-02-CANCER-05

Ambito

Internazionale

Località

Europa

Curatore

Marlene Faria

Dettagli Finanziari

Tipo di supporto

Fondo perduto

Tasso Massimo di Finanziamento

100%

Budget

26M€

Valore di Progetto Ammissibile

8M€ - 10M€

Durata Massima

60 mesi

Date e Scadenze

Data di Pubblicazione

5 ottobre 2026

Data di Apertura

10 febbraio 2026

Fase unica

16 settembre 2027 alle ore 17:00 GMT+2 (343 giorni rimanenti)

Descrizione

Objectives

This topic aims to support the pre-commercial procurement (PCP) of innovative and affordable solutions for healthcare systems in the areas of cancer technologies, medical devices and medicines, contributing directly to the implementation of the EU Mission on Cancer . The objective is to accelerate the development and validation of breakthrough solutions that address unmet needs in cancer prevention, diagnosis, treatment and patient care, while helping public healthcare providers become early adopters of innovation. The action seeks to bring together healthcare procurers, clinicians, researchers, patients, industry and public authorities to jointly steer the development of innovative solutions capable of improving cancer outcomes and increasing the sustainability and resilience of healthcare systems.

Funding

Funding is provided under a Horizon Europe Pre-Commercial Procurement (PCP) action within the framework of the EU Mission on Cancer . The topic has an indicative budget of €26 million , with the European Commission expecting to fund three projects. The expected EU contribution ranges between €8 million and €10 million per project , although proposals requesting different amounts may be considered if adequately justified.

As a HORIZON-PCP (Pre-Commercial Procurement) action, the funding supports the procurement of research and development services aimed at developing and validating innovative solutions that are not yet commercially available. The action enables groups of public procurers and healthcare organisations to jointly steer the development of new cancer-related technologies, medical devices and therapeutic solutions that address unmet healthcare needs.

Spese Ammissibili

- Personnel Costs
- Travel costs
- Equipment costs
- Other goods, works and services costs
- Subcontracting
- Indirect Costs

Idoneità

Settori Idonei

Salute e Life Sciences

Modalità di Candidatura

Aggregata / Partenariato

Tipologie Aziendali

- Microimpresa
- PMI
- Small Mid-Cap
- Mid-Cap

- Grande impresa
- Enti privati non profit
- Enti pubblici

Tipi di Azione

- Pre-Commercial Procurement
- Clinical studies
- Translational research
- Prevention and early detection initiatives
- Therapy development
- Patient support

Dettagli Programma UE

ID Bando

HORIZON-MISS-2027-02-CANCER-05

Cluster

Mission

Destinazione

Cancer

Modalità di Presentazione

Single-stage

Contributo UE

Around €8,000,000.00 to €10,000,000.00 per project

Progetti Previsti

3

Regola del Tasso di Finanziamento

The action is funded under Horizon Europe PCP rules, which allow reimbursement of up to 100% of eligible project costs for the beneficiaries involved in the procurement action

Link Ufficiali

Regolamento Ufficiale

<https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-MISS-2027-02-CANCER-05?order=DESC&pageNumber=1&pageSize=50&sortBy=startDate&keywords=HORIZON-MISS-2027-02-CANCER-05&isExactMatch=true&status=31094501,31094502,31094503>

Pagina Grantavia

<https://grantavia.com/it/incentives/pre-commercial-procurement-of-affordable-solutions-for-healthcare-systems-in-the-areas-of-cancer-technologies-cancer-medical-devices-or-cancer-medicines>

Prenota un incontro

<https://bookings.cloud.microsoft/book/Prenotaunappuntamento@epsa.com/?ismsaljsauthenabed>